BiotechTube

EQ001 + EQ001 Placebo

Phase 3Withdrawn
2 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Coronavirus

Conditions

Coronavirus

Trial Timeline

Nov 1, 2020 → Jun 1, 2021

NCT ID
NCT04605926

About EQ001 + EQ001 Placebo

EQ001 + EQ001 Placebo is a phase 3 stage product being developed by Biocon for Coronavirus. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04605926. Target conditions include Coronavirus.

What happened to similar drugs?

0 of 11 similar drugs in Coronavirus were approved

Approved (0) Terminated (1) Active (10)
❌Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
🔄Molnupiravir + PlaceboMerckPhase 3
🔄Efprezimod alfa + PlaceboMerckPhase 3
🔄Molnupiravir + PlaceboMerckPhase 3
🔄Canakinumab + PlaceboNovartisPhase 3
🔄anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)PfizerPhase 3
🔄Colchicine + Interferon-Beta + Aspirin + RivaroxabanBayerPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT04605926Phase 3Withdrawn
NCT03763318Phase 1/2Completed
NCT04007198Phase 1Completed

Competing Products

20 competing products in Coronavirus

See all competitors
ProductCompanyStageHype Score
COVID-19 VaccineModernaPreclinical
0
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
32
bamlanivimab 7000mg + BRII-196+BRII-198 + AZD7442 (IV) + AZD7442 (IM) + SNG001 + Camostat + BMS-986414 + BMS-986413 + SAB-185 (3,840 Units/kg) + SAB-185 (10,240 Units/kg) + CASIRIVIMAB + IMDEVIMAB + Placebo for Bamlanivimab 7000mg + Placebo for Bamlanivimab 700mg + Placebo for BRII-196+BRII-198 + Placebo for SNG001 + Placebo for Camostat + Placebo for SAB-185 (low dose) + Placebo for BMS-986414 + BMS-986413 + Placebo for AZD7442 (IV) + Placebo for AZD7442 (IM) + Placebo for SAB-185 (high dose) + bamlanivimab 700mgEli LillyPhase 2/3
38
Mesenchymal stem cellRohto PharmaceuticalPhase 1
29
ABBV-47D11 + Placebo for ABBV-47D11 + ABBV-2B04 + Placebo for ABBV-2B04AbbViePhase 1
29
Ibrutinib + PlaceboAbbViePhase 2
35
600 mg AZD7442 IV + 600mg placebo IVAstraZenecaPhase 2
35
EVUSHELDAstraZenecaPre-clinical
26
AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]) + AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])AstraZenecaPhase 2
27
AZD7442 IM + Placebo IM + AZD7442 IM + Placebo IM + AZD7442 IV + Placebo IV + AZD7442 IV + Placebo IVAstraZenecaPhase 1
29
Molnupiravir + PlaceboMerckPhase 3
40
Molnupiravir + PlaceboMerckPhase 2/3
38
V590MerckPhase 1
21
Molnupiravir + PlaceboMerckPhase 2/3
30
V591MerckPhase 1/2
24
Efprezimod alfa + PlaceboMerckPhase 3
40
M5049 + M5049 + PlaceboMerckPhase 2
35
Molnupiravir + PlaceboMerckPhase 3
47
Frespaciguat + PlaceboMerckPhase 1
21
Canakinumab + PlaceboNovartisPhase 3
40